By

Protect Access and Innovation
Cancer is frightening in the abstract, and even more so when it becomes your reality. Three years ago, I was diagnosed at a relatively young age with late-stage colon cancer and have since gone through extensive treatments.
Read More
"Californians have legitimate concerns about access to affordable drugs, but SB 17 does not address them. It is a bad deal for business and does nothing to benefit patients."
Read More
Small and innovative biopharmaceutical companies across California are currently investing in the life-saving treatments of tomorrow, creating well-paying jobs throughout the state and spurring economic growth.
Read More
"The California Assembly is considering Senate Bill 790 that would significantly limit both the amount and variations of benefits a pharmaceutical company can give to physicians."
Read More
"By focusing on list prices [in SB 17], Sen. Ed Hernandez distorts true costs, failing to ask whether drug discounts and rebates reach patients, or are pocketed by middlemen."
Read More
"The California Assembly is currently considering SB 17 that’s being deceptively sold under the label of drug pricing transparency." - Op-Ed in the San Diego Union-Tribune
Read More
"SB 17 would mean less innovation, less economic growth and less investment in our world-leading bioscience sector. It’s bad medicine for California."
Read More
Senate Bill 17, currently under consideration by the legislature, will not do anything to address the price that California consumers actually pay for medicine, and could jeopardize patient access to critical innovative medications.
Read More
"SB 17 is unlikely to result in lower drug prices. But it is highly likely it could drive down investment in new companies, reduce employment and slow development of new cures and treatments."
Read More
Americans are Paying More for Less Through Middlemen Like Pharmacy Benefit Managers.
Read More
1 2 3